Theriva Biologics, Inc.
TOVX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $27 |
| Gross Profit | $0 | $0 | $0 | -$27 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,551 | $1,953 | $2,968 | $2,886 |
| G&A Expenses | $1,889 | $11,179 | $1,273 | $0 |
| SG&A Expenses | $1,889 | $11,179 | $1,428 | $1,482 |
| Sales & Mktg Exp. | $0 | $0 | $155 | $0 |
| Other Operating Expenses | $0 | $0 | $21 | $0 |
| Operating Expenses | $4,440 | $13,132 | $4,417 | $4,368 |
| Operating Income | -$4,440 | -$13,132 | -$4,417 | -$4,395 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $79 | $74 | $93 | -$52 |
| Pre-Tax Income | -$4,361 | -$13,058 | -$4,324 | -$4,447 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,361 | -$13,058 | -$4,324 | -$4,447 |
| % Margin | – | – | – | – |
| EPS | -0.45 | -1.93 | -1.55 | -4.26 |
| % Growth | 76.7% | -24.5% | 63.6% | – |
| EPS Diluted | -0.45 | -1.93 | -1.55 | -1.6 |
| Weighted Avg Shares Out | 9,677 | 6,753 | 2,782 | 1,348 |
| Weighted Avg Shares Out Dil | 9,677 | 6,753 | 2,782 | 1,348 |
| Supplemental Information | – | – | – | – |
| Interest Income | $65 | $54 | $96 | $138 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $28 | $27 | $26 | $27 |
| EBITDA | -$4,333 | -$13,105 | -$4,370 | -$4,420 |
| % Margin | – | – | – | – |